|
|
 |
Genomic Health strives
to ease the burden |
 |
 |
New regulation could
impact patient access |
|
 |
More than 530 sites now
enrolling patients |
|
 |
New resource demystifies
genetic and genomic science |
|
 |
Don't miss this event,
hosted by Genomic Health |
|
 |
Genomic Health Corporate Site
www.genomichealth.com
MyTreatmentDecision.com
www.mytreatmentdecision.com
Oncotype DX
www.oncotypeDX.com
|
|
As the TAILORx trial enrolls patients around the country – and around the world – we at Genomic Health continue to be encouraged by high level of interest in the landmark trial.
Since our last newsletter update in August, more than 400 new sites have opened, and there are currently more than 530 total sites now enrolling patients.
As we continue toward the goal of enrolling 11,000 women, we thank you for your support of this trial and encourage you to share information with your peers and constituents on TAILORx trial eligibility and enrolling sites.
As a reminder for you and your constituents, the TAILORx trial is designed for patients with newly-diagnosed, early stage breast cancer. All patients who agree to participate in the trial will have the Oncotype DX™ test performed on a sample of the tumor that has already been removed.
Patients participating in the TAILORx clinical trial will not be responsible for the cost of the Oncotype DX test.
Additional resources on this trial continue to be made available and below are links to more information on the TAILORx clinical trial.
-
NCI provides links to the TAILORx protocol with a listing of active sites, a press release with information on the trial, and general information on molecular diagnostics, at www.cancer.gov/clinicaltrials/digestpage/TAILORx
-
ECOG provides new TAILORx patient fact sheets, a list of hospitals and physicians offering TAILORx, and general information on clinical trials at www.ecog.org/general/tailorx.html
-
Genomic Health provides additional information on the Oncotype DX assay at www.oncotypeDX.com
|
|